$TCRT
Alaunos Therapeutics, Inc.

2015 Q4 Form 10-Q Financial Statement

#000119312515362281 Filed on November 02, 2015

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2014 Q3
Revenue $1.920M $1.870M $630.0K
YoY Change 464.71% 196.83% 215.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.260M $3.070M $2.840M
YoY Change 14.39% 8.1% -7.49%
% of Gross Profit
Research & Development $8.140M $16.97M $9.733M
YoY Change 0.62% 74.36% 55.8%
% of Gross Profit
Depreciation & Amortization $60.00K $60.00K $120.0K
YoY Change -50.0% -50.0% -33.33%
% of Gross Profit
Operating Expenses $11.40M $16.97M $9.733M
YoY Change 4.2% 74.36% 55.8%
Operating Profit -$9.482M -$18.17M -$11.94M
YoY Change -10.51% 52.12% 31.01%
Interest Expense $0.00 $0.00 $5.850M
YoY Change -100.0% -100.0% -178.95%
% of Operating Profit
Other Income/Expense, Net $10.00K -$4.000K $2.000K
YoY Change -300.0% -101.05%
Pretax Income -$9.480M -$18.17M -$6.090M
YoY Change -8.85% 198.36% -63.55%
Income Tax
% Of Pretax Income
Net Earnings -$9.476M -$18.17M -$6.093M
YoY Change -8.89% 198.21% -63.54%
Net Earnings / Revenue -493.54% -971.66% -967.14%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.07 -$0.14 -$0.06
COMMON SHARES
Basic Shares Outstanding 130.9M shares 130.9M shares 100.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $140.7M $163.8M $46.10M
YoY Change 228.74% 255.31% 95.34%
Cash & Equivalents $140.7M $163.8M $46.12M
Short-Term Investments
Other Short-Term Assets $11.40M $8.300M $1.500M
YoY Change 936.36% 453.33% -53.13%
Inventory
Prepaid Expenses
Receivables $400.0K $400.0K $200.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $152.5M $172.5M $47.81M
YoY Change 245.95% 260.73% 75.3%
LONG-TERM ASSETS
Property, Plant & Equipment $581.0K $262.0K $654.0K
YoY Change 9.42% -59.94% -51.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $494.0K $491.0K $513.0K
YoY Change 0.61% -4.29% -30.58%
Total Long-Term Assets $1.203M $881.0K $1.295M
YoY Change 4.61% -31.97% -41.22%
TOTAL ASSETS
Total Short-Term Assets $152.5M $172.5M $47.81M
Total Long-Term Assets $1.203M $881.0K $1.295M
Total Assets $153.7M $173.4M $49.11M
YoY Change 239.82% 253.01% 66.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.008M $4.154M $1.953M
YoY Change 0.2% 112.7% 119.19%
Accrued Expenses $8.906M $18.14M $7.803M
YoY Change 24.0% 132.45% -32.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.12M $29.63M $11.70M
YoY Change 67.4% 153.22% -12.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $48.20M $49.90M $20.00K
YoY Change 7933.33% 249400.0% 0.0%
Total Long-Term Liabilities $48.20M $49.90M $20.00K
YoY Change 7933.33% 249400.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.12M $29.63M $11.70M
Total Long-Term Liabilities $48.20M $49.90M $20.00K
Total Liabilities $66.35M $79.52M $12.63M
YoY Change 482.25% 529.51% -51.13%
SHAREHOLDERS EQUITY
Retained Earnings -$492.7M -$483.2M -$362.2M
YoY Change 32.23% 33.41%
Common Stock $580.1M $577.1M $398.7M
YoY Change 42.72% 44.74% 20.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $87.37M $93.84M $36.48M
YoY Change
Total Liabilities & Shareholders Equity $153.7M $173.4M $49.11M
YoY Change 239.82% 253.01% 66.6%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2014 Q3
OPERATING ACTIVITIES
Net Income -$9.476M -$18.17M -$6.093M
YoY Change -8.89% 198.21% -63.54%
Depreciation, Depletion And Amortization $60.00K $60.00K $120.0K
YoY Change -50.0% -50.0% -33.33%
Cash From Operating Activities -$23.80M $45.20M -$10.49M
YoY Change 141.13% -530.89% -32.32%
INVESTING ACTIVITIES
Capital Expenditures $380.0K $10.00K $90.00K
YoY Change -88.89%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$380.0K -$10.00K -$90.00K
YoY Change -88.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.070M 90.00K 3.700M
YoY Change -83.66% -97.57% 1750.0%
NET CHANGE
Cash From Operating Activities -23.80M 45.20M -10.49M
Cash From Investing Activities -380.0K -10.00K -90.00K
Cash From Financing Activities 1.070M 90.00K 3.700M
Net Change In Cash -23.11M 45.28M -6.880M
YoY Change 596.08% -758.14% -55.03%
FREE CASH FLOW
Cash From Operating Activities -$23.80M $45.20M -$10.49M
Capital Expenditures $380.0K $10.00K $90.00K
Free Cash Flow -$24.18M $45.19M -$10.58M
YoY Change 144.98% -527.13% -31.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46122000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3579108 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3655135 shares
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.09
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3441950 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.09
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2015Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
130887901 shares
CY2015Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1886001 shares
CY2015Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.69
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
130887901 shares
CY2015Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
29627000
CY2015Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
49514000
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18138000
CY2015Q3 us-gaap Liabilities
Liabilities
79520000
CY2015Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
402000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
131000
CY2015Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
576934000
CY2015Q3 us-gaap Deferred Rent Credit
DeferredRentCredit
781000
CY2015Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6933000
CY2015Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-483224000
CY2015Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
379000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
93841000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
173361000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4154000
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
104452105 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3781162 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
262000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
172480000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16481000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
16139000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163843000
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9277000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.07
CY2015Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
369000
CY2015Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
5100000
CY2015Q3 us-gaap Assets
Assets
173361000
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8268000
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
491000
CY2015Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2015Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
130888901 shares
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68204000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6505663 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.10
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104452105 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10826000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7182000
CY2014Q4 us-gaap Liabilities
Liabilities
11396000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
280000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
104000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
406349000
CY2014Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
850000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1360000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-372612000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
570000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
33841000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45237000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2004000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
531000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
44087000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42803000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4130000
CY2014Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
145000
CY2014Q4 us-gaap Assets
Assets
45237000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1139000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
491000
CY2014Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2015Q1 us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15 million and no greater than $20 million per year.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
114300 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14310937 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26780000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.15
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100360825 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
193000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
us-gaap Operating Income Loss
OperatingIncomeLoss
-32903000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
63000
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
132000
us-gaap Interest Paid
InterestPaid
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-464000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-15000
us-gaap Net Income Loss
NetIncomeLoss
-21380000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
11529000
us-gaap Contracts Revenue
ContractsRevenue
1033000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
445000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
339000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4891000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-154000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9315000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
33936000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1033000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-22082000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3700000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
692000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1531000
us-gaap Share Based Compensation
ShareBasedCompensation
3583000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1447000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-193000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1323000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24621000
ziop Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
2292362 shares
ziop Stock Issued During Period Shares Stock Warrants Exercised
StockIssuedDuringPeriodSharesStockWarrantsExercised
1991409 shares
dei Document Type
DocumentType
10-Q
dei Trading Symbol
TradingSymbol
ZIOP
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
254800 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Document Period End Date
DocumentPeriodEndDate
2015-09-30
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4782838 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
167167 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M2D
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.61
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
23792000
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.13
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.96
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2938161 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.10
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
123911796 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M2D
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y7M2D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M2D
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25000
us-gaap Stock Issued1
StockIssued1
67285000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
94320000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6054000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000
us-gaap Operating Income Loss
OperatingIncomeLoss
-110618000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
224000
us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
379000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
67285000
us-gaap Interest Paid
InterestPaid
0
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3366000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7129000
us-gaap Net Income Loss
NetIncomeLoss
-110612000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
34000
us-gaap Contracts Revenue
ContractsRevenue
2413000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
94320000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
581000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
295000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
97273000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-69000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14388000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
113031000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
55087000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
121040000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
379000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
67285000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2150000
us-gaap Stock Redeemed Or Called During Period Value
StockRedeemedOrCalledDuringPeriodValue
34000
us-gaap Share Based Compensation
ShareBasedCompensation
6054000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
10956000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
267000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
201000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-25000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3366000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
98643000
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9236 pure
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11942000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-6093000
ziop Research And Development Service Agreement Quarterly Payment
ResearchAndDevelopmentServiceAgreementQuarterlyPayment
7500000
ziop Common Stock Warrants Expiration Date
CommonStockWarrantsExpirationDate
2014-12
ziop Change In Research And Development Expenses
ChangeInResearchAndDevelopmentExpenses
372000
CY2009 ziop Class Of Warrant Term
ClassOfWarrantTerm
P5Y
CY2009 ziop Warrants To Purchase Aggregate Shares Of Common Stock
WarrantsToPurchaseAggregateSharesOfCommonStock
8206520 shares
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
325000
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
10000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0203 pure
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.29
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
100428520 shares
CY2014Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
5847000
CY2014Q3 us-gaap Contracts Revenue
ContractsRevenue
633000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2842000
CY2014Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
12575000
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1148000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9733000
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
203000 shares
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.49
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
129732356 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18166000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-18170000
CY2015Q3 us-gaap Contracts Revenue
ContractsRevenue
1869000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3065000
CY2015Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
20035000
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1477000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16970000

Files In Submission

Name View Source Status
0001193125-15-362281-index-headers.html Edgar Link pending
0001193125-15-362281-index.html Edgar Link pending
0001193125-15-362281.txt Edgar Link pending
0001193125-15-362281-xbrl.zip Edgar Link pending
d86685d10q.htm Edgar Link pending
d86685dex311.htm Edgar Link pending
d86685dex312.htm Edgar Link pending
d86685dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g86685g13y31.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20150930.xml Edgar Link completed
ziop-20150930.xsd Edgar Link pending
ziop-20150930_cal.xml Edgar Link unprocessable
ziop-20150930_def.xml Edgar Link unprocessable
ziop-20150930_lab.xml Edgar Link unprocessable
ziop-20150930_pre.xml Edgar Link unprocessable